Following a full submission.
Salmeterol / fluticasone (Seretide Accuhaler) is accepted for use within NHS Scotland for the treatment of patients with severe chronic obstructive pulmonary disease.
It is the first of two long-acting 2-agonist / corticosteroid combination inhaler preparations considered by SMC and licensed for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD). The individual components have been available for many years and the combination product offers ease of administration and additional convenience. The combination appears to improve lung function to a greater extent than either of the individual constituents given alone. Comparative data with other combination products are limited at the present time.
Download detailed advice22KB (PDF)
- Medicine name:
- Fluticasone, salmeterol (Seretide Accuhaler®)
- SMC ID:
- Severe chronic obstructive pulmonary disease
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Date advice published
- 08 December 2003